ESSITY-B

Essity AB occupies a peculiar position in European consumer staples. It is simultaneously one of the most structurally embedded companies in global hygiene, and one of the least visible to the average equity investor. Spun out of Svenska Cellulosa Aktiebolaget (SCA) in 2017, Essity inherited a portfolio of brands and institutional relationships built over more than 170 years. Yet the company trades at roughly SEK 245 per share, a fraction of the SEK 767 implied by discounted cash flow models, suggesting a market that either undervalues the structural position or correctly prices in growth skepticism. That gap is the analytical puzzle at the center of this analysis.

The company operates across three core segments: Personal Care (anchored by the TENA incontinence brand), Consumer Tissue (Tempo, Lotus, Regio, and the Vinda joint venture in Asia), and Professional Hygiene (built on the TORK brand). Full-year 2025 revenue came in at SEK 138.5 billion, with an EBIT margin of 13.4% and net income of SEK 12.7 billion. These are not the figures of a company in distress. They are the figures of a company navigating a transition from price-driven growth to volume-driven growth after the inflationary wave of 2021 to 2023.

What makes Essity analytically interesting is not the products it sells, but how those products are purchased. In Professional Hygiene, TORK dispensers are physically installed in commercial buildings, hospitals, airports, and stadiums. Once installed, the dispenser creates a closed purchasing loop: facilities managers reorder TORK refills because the dispenser accepts only TORK products. This is not brand preference. It is physical lock-in. In Health and Medical, TENA incontinence products are specified by healthcare procurement departments, embedded in care protocols, and purchased through multi-year institutional contracts. The switching cost is not financial; it is procedural, reputational, and regulatory. A hospital that changes incontinence suppliers must retrain staff, validate new products against infection control standards, and accept risk during the transition period. Few procurement officers are willing to accept that risk for marginal cost savings.

Essity does not disrupt. Essity makes disruption irrelevant by embedding itself in the physical and procedural infrastructure of daily life. The central question is whether this structural entrenchment can translate into shareholder returns, or whether the company's low-growth profile and valuation discount are permanent features of a defensive compounder in a market that rewards momentum.